Last reviewed · How we verify
HPV 4
At a glance
| Generic name | HPV 4 |
|---|---|
| Sponsor | Beijing Chaoyang District Centre for Disease Control and Prevention |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer (PHASE3)
- Using Artificial Intelligence-based ChatBot to Improve Women's Participation to Cervical Cancer Screening Programme (NA)
- Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines (PHASE4)
- Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer (PHASE2)
- Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC (PHASE2)
- CUE-101with Pembrolizumab for LA-HPV+HNSCCs (PHASE2)
- Comparison Between Liquid-Based Cytology And Molecular Screening For Detecting Precursor Lesions and Cervical Cancer (NA)
- Clinical Trial Evaluating Secondary HPV Vaccination After Treatment of High-grade Cervical Lesions (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HPV 4 CI brief — competitive landscape report
- HPV 4 updates RSS · CI watch RSS
- Beijing Chaoyang District Centre for Disease Control and Prevention portfolio CI